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Abstract
Background: Although an important source of treatment for fevers, little is known about the
structure of the retail sector in Africa with regard to antimalarial drugs. This study aimed to assess
the range, costs, sources and registration of antimalarial drugs in the Kenyan retail sector.
Methods: In 2002, antimalarial drug registration and trade prices were established by triangulating
national registration lists, government gazettes and trade price indices. Data on registration status
and trade prices were compared with similar data generated through a retail audit undertaken
among 880 randomly sampled retailers in four districts of Kenya.
Results: Two hundred and eighteen antimalarial drugs were in circulation in Kenya in 2002. These
included 65 "sulfur"-pyrimethamine (sulfadoxine-pyrimethamine and sulfalene-pyrimethamine (SP),
the first-line recommended drug in 2002) and 33 amodiaquine (AQ, the second-line recommended
drug) preparations. Only half of SP and AQ products were registered with the Pharmacy and
Poisons Board. Of SP and AQ brands at district level, 40% and 44% were officially within legal
registration requirements. 29% of retailers at district level stocked SP and 95% stocked AQ. The
retail price of adult doses of SP and AQ were on average 0.38 and 0.76 US dollars, 100% and 347%
higher than trade prices from manufacturers and importers. Artemether-lumefantrine, the newly
announced first-line recommended antimalarial drug in 2004, was found in less than 1% of all retail
outlets at a median cost of 7.6 US dollars.
Conclusion: There is a need to ensure that all antimalarial drugs are registered with the Pharmacy
and Poisons Board to facilitate a more stringent post-marketing surveillance system to ensure drugs
are safe and of good quality post-registration.
Background
Drugs' retailers play an important role in the management
of childhood fevers in Africa [1,2]. The extent of self-med-
ication with proprietary drugs from retailers varies across
the continent and has been reported to be as low as 19%
in Guinea to as high as 94% in some parts of rural Ghana
[3]. Reasons for reported use of the retail sector for fever
management are diverse, ranging from ease of geographi-
cal access [4] to economic accessibility [5] and perceived
failures of the formal health sector [3,6].
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The World Health Organization (WHO) has recognised
the role of the retail sector in helping to meet interna-
tional targets on prompt access to antimalarial drugs
[2,7]. Despite the renewed interest in home-based care,
there is still a relatively poor understanding of the struc-
ture of the retail sector compared to our knowledge of for-
mal service providers. While there has been a plethora of
research on the use of the retail sector by communities in
malaria endemic areas of Africa [8], complimented by a
few studies on the knowledge of antimalarial drugs by
service providers in the retail sector [9-12], to-date there
has been only one study that has characterized the struc-
ture of the retail sector with respect to antimalarial drug
ranges and sources, and how these relate to the national
supply [13].
In Kenya, the retail sector is an important source of treat-
ment for fevers [9,14-19] and the aim of this paper is to
characterize the antimalarial drug products provided by
this sector in terms of legal status, product ranges, costs
and sources. The results focus on first and second-line
treatment for uncomplicated malaria at the time of the
studies, "sulfur"-pyrimethamine (sulfadoxine-pyrimeth-
amine and sulfalene-pyrimethamine, SP) and amodi-
aquine (AQ), respectively. Issues related to the availability
of other antimalarial products, including those that are no
longer promoted as efficacious (chloroquine) and those
that will serve as replacement therapies for SP and AQ in
2005 (the artemisinins) are highlighted.
Methods
National antimalarial audit
A national list of all registered antimalarial drugs was
obtained from the Pharmacy and Poisons Board (PPB) of
the Ministry of Health (MoH) [20,21] and updated
through a series of reviews of minutes of the PPB and
Kenya Gazette notices. Gazette notices are provided by the
Government Printers and notify the public of registration
of new products. The Committee for Drug Registration
(CDR) of the PPB registers drugs based on their safety,
quality and efficacy and unregistered drugs are considered
illegal. Applicants pay 500 US dollars for Kenyan products
and 1,000 US dollars for imported products per applica-
tion. Registration is valid for five years, after which a re-
registration is sought from the CDR for a further five years
with a second fee of 300 US dollars and 500 US dollars for
local and imported products respectively.
The official PPB list was augmented by two commercially
available drugs and medical devices price lists [22,23],
published yearly or bi-monthly, and serving as national
trade indices. These lists provided information not availa-
ble from the PPB sources. Information collected from all
sources included brand names, dosage forms, strengths,
manufacturers, trade packs, trade costs and product regis-
tration status and registration dates. The composite
national antimalarial database was finalized on May 31,
2002 to enable comparison with subsequent retail audits
at district level.
Retail audit survey procedures
A retail audit was undertaken between February and June
2002 in four malaria monitoring sentinel districts: Kwale
in Coast Province, Makueni in Eastern Province, Greater
Kisii in the western highlands and Bondo on the shores of
Lake Victoria. These are described elsewhere in detail
[4,19,24].
A national census of retailers was developed between
1999 and 2000 by a commercial market research organi-
sation. Data for each of the four sentinel districts were
purchased and used to identify outlets that stocked and
sold antimalarial or antipyretic products at the time of the
retail census. Data were then displayed in MapInfo (Ver-
sion 6.0, 1985–2000) and physical addresses compared
against coordinates of market centres obtained from top-
ographic maps and GPS data from various sources [4,25].
Any errors in positioning the 1999–2000 data were then
corrected and positions of outlets redefined to the market
centre. Outlets were categorized into pharmacies, large
retailers (defined crudely as stores with more than one
person serving customers during normal working hours),
and small retailers (defined as outlets with only one per-
son serving customers during normal working hours).
Outlets were then sampled based upon the estimates of
the numbers of retail outlets in each district and the
expected prevalence of SP stocks (assumed to be 50%) to
achieve between 5–10% precision and 95% confidence in
the parameters of interest. A minimum of 20 pharmacies
in each district was targeted, large retailers were randomly
sampled to achieve a minimum of 40 outlets per district,
and a random sample of 160 small retailers per district
was selected.
Between February and May 2002, districts were visited to
a) confirm which outlets in the sampling frame were
retailing antimalarial drugs (the main drugs of interest);
b) establish precise geographical positions of the outlet
using a hand-held GPS unit (Magellan GPS 315 or
Garmin etrex); and c) obtain permission from shopkeep-
ers for a more indepth interview at a later date. In June
2002, a retail audit was undertaken among retailers who
consented to the capture of information on brands of
antimalarial drugs, pharmacological groups, wholesale
source and retail costs. Data were entered twice using MS-
Access 2000 (Microsoft Corp., Redmond, USA) developed
data-entry screens, verified and cleaned. Data were ana-
lysed using a combination of MS Excel 2000 (Microsoft
Corp., Redmond, USA) and SPSS version 9.0 for WindowsMalaria Journal 2005, 4:36 http://www.malariajournal.com/content/4/1/36
Page 3 of 6
(page number not for citation purposes)
(SPSS Inc., Chicago, USA) and presented as proportions,
medians and interquartile ranges.
Results
Range of products at the national level
One hundred and thirty five oral antimalarial products
registered with the PPB were identified. Of these, registra-
tion dates were gazetted for 122 (90.4%), the remaining
13 (9.6%) were noted in the minutes of the CDR as
approved for registration, but no registration dates or ref-
erence numbers were available. Of the 122 products for
which details were available, only 40 (32.8%) were within
their five-year registration period, and 82 (67.2%) were
due for re-registration. It is possible that some products in
the latter group had been granted marketing approval by
the PPB, but were awaiting final gazettement and registra-
tion (and could, therefore, not be found on official lists)
or that the manufacturers and dealers no longer marketed
these products and had, therefore, allowed registration to
lapse. Of those with an expired registration status, how-
ever, 39 (47.6%) were identifiable on the commercial
trade indices, suggesting they were still marketed in
Kenya.
83 products were identified that were not on the PPB list,
but were available on commercial lists. It is estimated,
therefore, that 218 oral antimalarial products were in cir-
culation in 2002. Of these products, 92 (42.2%) were
manufactured locally and 126 (57.8%) were products
imported from overseas.
Table 1 shows the overall registration status of the 218
products according to the various antimalarial classes.
From the national audit, 34/65 (52.3%) of SP products
were registered, while 17/33 (51.5%) of AQ products were
registered with the PPB. All artemisinin (ART) tablets,
mefloquine (MEF) tablets and halofantrine (HAL) prod-
ucts were registered, while none of the ART suspensions
were registered.
Range of antimalarial drug classes and formulations at 
district level
Eight hundred and eighty retailers were sampled, but four
were excluded from analysis since the shops remained
closed even after three visits (Table 1). Overall, SP was
stocked by 28.7% of retailers and AQ by 94.7%. Chloro-
quine (CQ), which had been replaced by SP in 1998 as the
first-line recommended drug, was still available in 15.4%
of retail outlets. Other antimalarial drugs were available
in less than 10% of retail outlets. SP and AQ tablets were
the most widely stocked formulations (28.5% and 93.4%,
respectively) and were available in pharmacies, large
retailers, and small retailers. ART, HAL and MEF were sold
exclusively in pharmacies.
Table 1: National and retail audit of oral anti-malarial drugs available on the Kenyan market in 2002
National audit Retail audit
Generic Name # Brands 
identified 
(registered)*
Median (IQR) 
cost (USD) of 
treatment course†
# Brands 
identified 
(registered)*
# Outlets 
stocking (%)
Median (IQR) 
cost (USD) of 
treatment course†
SP tablets 49 (29) 0.19 [0.13, 0.32] 30 (16) 250 (28.5%) 0.38 [0.25, 0.65]
SP suspensions and drops‡ 16 (5) 0.39 [0.28, 0.53] 15 (2) 57 (6.5%) 0.44 [0.44, 0.56]
AQ tablets 22 (12) 0.17 [0.14, 0.55] 13 (6) 818 (93.4%) 0.76 [0.76, 0.76]
AQ suspensions 11 (5) 0.28 [0.15, 0.49] 12 (5) 71 (8.1%) 0.51 [0.39, 0.60]
CQ tablets 43 (33) 0.09 [0.08, 0.19] 12 (5) 132 (15.1%) 0.44 [0.25, 0.44]
CQ syrups 22 (10) 0.05 [0.03, 0.30] 9 (4) 12 (1.4%) 0.26 [0.06, 0.31]
QN tablets 25 (19) 2.73 [2.40, 3.16] 3 (2) 32 (3.7%) 3.20 [2.40, 4.00]
QN drops and mixtures 3 (1) 2.24 [1.87, 3.00] 4 (1) 49 (5.6%) 4.00 [3.27, 4.00]
ART tabs 11 (11) 5.34 [4.16, 5.56] 7 (7) 24 (2.7%) 7.11 [6.14, 7.96]
ART suspensions 1 (0) 3.86 [3.86, 3.86] 2 (0) 21 (2.4%) 5.00 [4.44, 5.13]
MEF tablets 4 (4) 5.04 [3.83, 9.53] 4 (4) 14 (1.6%) 7.61 [7.33, 7.87]
HAL tablets 1 (1) 7.96 [7.96, 7.96] 1 (1) 22 (2.5%) 9.90 [9.26, 10.25]
HAL suspensions 1 (1) 2.83 [2.83, 2.83] 1 (1) 18 (2.1%) 3.55 [3.20, 3.71]
Other tablets 9 (6) 3.62 [0.35, 13.20] 1 (1) 18 (2.1%) 17.51 [17.51, 17.51]
* Registration period covers up to and including May 31, 2002.
† For packaged commodities, the calculations were derived per tablet and per recommended dose for adults. Where possible, large, bulk packaging 
was selected for individual suppliers to provide the cheapest values for the national audit.
‡ Liquid dosage forms (suspensions, syrups, mixtures and paediatric drops) were all costed per dosage per child aged 1–5 years – not adult 
treatment courses. The mean dose per product was calculated as the mid-point between the Division of Malaria Control (DOMC) recommended 
dose for a 1 year old (lower limit of 10 kg) and a 5 year old (upper limit of 18 kg).Malaria Journal 2005, 4:36 http://www.malariajournal.com/content/4/1/36
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Range, availability and registration of antimalarial brands 
at district level
Thirty brands of SP tablets were identified in the districts
(Table 1), the two most widely stocked being Falcidin®
(stocked by 19.9% of outlets, Cosmos Limited, Kenya)
and Fansidar® (8.8%, L. Hoffmann La Roche, Switzer-
land). Sixteen SP brands (53.3%) were registered with the
PPB. Zentakelfin®, Sudorin® and Lansidar®, all unregis-
tered, were available in some district level pharmacies and
not recorded during the national audit. Fifteen brands of
SP suspensions were also found, yet only two were regis-
tered with the PPB.
For AQ tablets, 13 brands were identified of which six
(46.2%) were registered with the PPB. Three brands
(which were not registered) were identified in the districts
and were not recorded during the national audit:
Amowin®, Vanida®, and Maratab®. Malaratab® (Cosmos
Limited, Kenya) was the most widely stocked AQ tablet,
found in 87.9% of outlets. Twelve brands of AQ syrup
were encountered with only five (41.7%) registered with
the PPB.
Of interest was that all higher order antimalarial tablets,
such as quinine (QN), HAL, MEF and ART class of drugs,
were to a large extent all registered with the PPB and
mostly available in pharmacies. The exception was one
QN tablet formulation. Conversely, only 2/5 (40%) of the
higher order antimalarial syrups were registered.
Wholesale sources of antimalarial drugs to district level 
retailers
Due to the wide range of products in pharmacies, it was
not possible to ask the wholesale source of individual
products. Respondents were asked the primary wholesale
source of antimalarial drugs in stock at the time. For large
and small retailers, the source of each product audited was
established. The wholesale source of most products in
stock was adopted as the primary source of antimalarial
drugs for each outlet. Drug sources thus defined were clas-
sified in eight groups as shown in Table 2. Results show
that overall pharmacies obtained their antimalarial drugs
from pharmaceutical wholesalers outside the districts
(67.1%). Large retailers obtained their drugs from general
wholesalers outside the districts (39.8%) or inside the dis-
trict (34.8%). Most small retailers (45.3%) obtained anti-
malarial drugs from general wholesalers within the
districts. A substantial proportion of small retailers
(23.3%) also obtained their antimalarial drugs from gen-
eral wholesalers outside the districts. Mobile vendors sup-
plied a good number of small retailers (14.0%) and large
retailers (7.5%), but not pharmacies.
Trade versus retail costs of antimalarial drugs
For product costs, standardized dose regimens were used
to enable comparisons between the antimalarial classes.
SP, AQ, CQ and QN doses were based on the malaria
standard treatment guidelines set by the DOMC of the
MoH [26]. For all other antimalarial drugs (which are not
the subject of DOMC guidelines), the East African Phar-
maceutical Loci, a regional formulary for healthcare pro-
fessionals, was used [22]. Costs were calculated in US
dollars (USD) based on the Central Bank of Kenya rates at
the time of the survey (June 2002).
For trade prices, large bulk packaging was selected per sup-
plier to provide the cheapest factory gate costs (Table 1).
The trade price for an adult dose of SP was 0.19 USD (IQR
0.13, 0.32), while a standard dose for a paediatric patient
on SP suspensions cost nearly twice as much. AQ tablet
and suspension prices were 0.17 USD for an adult dose
and 0.28 USD for a paediatric suspension. The trade price
range for QN, MEF, HAL and ART products was between
2.24 and 7.96 USD (Table 1).
Retail prices at the district level were standardized to an
adult and paediatric dose as described above and are
shown in Table 1. The retail price for an adult dose of SP
Table 2: Primary wholesale sources of antimalarial products to 876* retailers in the four study districts.
Totals
Pharmacies Large Shops Small Shops
Mobile vendors 0 12 (7.5%) 90 (14.0%)
General wholesalers-within district 0 56 (34.8%) 292 (45.3%)
General wholesaler-outside district 2 (2.9%) 64 (39.8%) 150 (23.3%)
Pharmaceutical wholesaler-within district 17 (24.3%) 11 (6.8%) 51 (7.9%)
Pharmaceutical wholesaler-outside district 47 (67.1%) 3 (1.9%) 13 (2.0%)
Pharmaceutical company 2 (2.9%) 3 (1.9%) 0
Drug representative 0 7 (4.3%) 5 (0.8%)
Unknown 2 (2.9%) 5 (3.1%) 44 (6.8%)
* Four small retailers were excluded from analysis since they remained closed even after three repeated visits.Malaria Journal 2005, 4:36 http://www.malariajournal.com/content/4/1/36
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was 0.38 USD (IQR 0.25, 0.65), while a standard dose for
a paediatric patient on SP suspension was 0.44 USD (IQR
0.44, 0.56). AQ tablet prices were 0.76 USD (IQR 0.76,
0.76), while AQ suspension cost a median of 0.51 USD
(0.39, 0.60). The retail price range for QN, MEF, HAL and
ART products was between 3.55 to 9.90 USD (Table 1).
The two most widely stocked brands of SP and AQ tablets
(Falcidin® and Malaratab®, respectively) are used to dem-
onstrate retail mark-ups on trade costs. The trade cost for
an adult treatment course of Falcidin® in May 2002 was
0.15 USD, while that for Malaratab® was 0.55 USD. The
equivalent median retail prices for the two products were
0.32 USD and 0.76 USD, respectively, representing a
113% and 38% mark-up on the trade price.
Discussion
There was a wide range of antimalarial products available
in the Kenyan retail market in 2002. However, not all
nationally marketed first- and second-line drugs were in
circulation in the peripheral retail sector; 17 preparations
of SP (26%) and five (15%) of AQ were not detected at the
district level. Conversely, there were three brands of SP
and three of AQ which were in retail circulation at the dis-
trict level, but which had not been identified during the
central audit and were unregistered by the PPB. One seri-
ous consequence of a wide range of products available to
largely biomedically ill-informed, rural populations is
brand confusion, which may lead to unintentional
repeated doses of the same drug class and consequently,
dose-dependent adverse effects [27]. Moreover, the avail-
ability of unregistered products poses a danger to malaria
treatment since the safety, efficacy and quality of such
drugs cannot be guaranteed [28].
The most widely available antimalarial in the retail sector
was AQ, sold in 95% of outlets surveyed. AQ was a pre-
scription-only medication (POM) and regarded as the sec-
ond-line treatment at the time of the survey. In contrast,
SP, the first-line drug in 2002, was available in only 29%
of outlets surveyed. The situation was found to be differ-
ent in neighbouring Tanzania when CQ was still the first-
line drug for uncomplicated malaria. 33% of general
retailers and 98% of pharmacies stocked CQ. Conversely
SP, the second-line treatment, was sold in less than1% of
general retailers and in 37% of pharmacies [13]. Although
the apparent policy-practice disconnect in Kenya in drug
scheduling and national malaria policy could be attrib-
uted to a more prolific and unregulated retail market in
antimalarial drugs compared to Tanzania, a more plausi-
ble explanation is a lack of a concerted national effort to
inform populations about changes in drug policy. In the
absence of strong government action to back up new drug
policies (e.g. mass communication, training of health
workers, etc.), market forces will fill the gap and dictate
the stocking of antimalarial drugs by retailers. Closer
cooperation and consultation with local pharmaceutical
manufacturers and importers of antimalarial drugs during
national policy change and broad, high profile, commu-
nity-wide communication strategies for drug policy
change are critical for successful implementation.
Compared to the national trade price data, mark-ups are
between 100–347% (using SP and AQ tablets as exam-
ples) when they reach the peripheral retail level. Retailers
represent the last link in a chain of manufacturers/drug
importers and wholesalers, and it is not clear from the
results if the high price mark-ups on antimalarial drugs
are transferred from these primary/middle level suppliers
to the retailer or these represent retailer pricing structures.
More formative research is required to understand the
pricing structure for antimalarial drugs in the retail sector
to identify opportunities to reduce costs and retail profit
margins with new medicines such as artemisinin-based
combination therapies (ACTs).
At the time of this study, the artemisinins (potential
replacements to SP monotherapy) were only available in
pharmacies in Kenya. More importantly, the proposed
new first-line drug for Kenya, artemether-lumefantrine
(registered in Kenya in July 1999 as Coartem®), was avail-
able in 8/70 (11%) of district level pharmacies (i.e. less
than 1% of all retailers) at a median cost of 7.6 US dollars
(interquartile range 6.2, 10.1). This represents a huge cost
to households which invariably bear most of the cost of
treating malaria [29].
Conclusion
The studies show that when drug classes become estab-
lished treatments, many branded options soon become
available on the retail market. In Kenya, the regulation of
this plethora of brands is weak: many do not go through
the regulatory pipeline and for those that do, there is little
follow-up post-registration. In addition, antimalarial drug
prices vary widely within the same drug class. During the
era of ACTs, there is a need to ensure that these new drugs
are registered and monitored post-registration to ensure
their continued safety, quality and efficacy. Regulatory
mechanisms and price controls must be strengthened and
enforced to improve the use of drugs in the retail sector.
In addition, nation-wide, high profile communication
strategies should accompany drug policy changes to bring
demand for antimalarial drugs in line with policy.
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